Immune checkpoint inhibitors have rewritten the rules of modern cancer care, unleashing the body’s own defenses against ...

Immune cells often manage to reach head and neck tumors, but once inside, many of them stop doing their job. That paradox has ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

Neoadjuvant immune checkpoint blockade (ICB) has shown unprecedented activity in mismatch repair deficient (MMRd) colorectal cancers, but its effectiveness in MMRd endometrial cancer (EC) remains ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

ICI unmet need through differentiated, biomarker-guided therapies, strategic pipeline prioritization, competitive benchmarking, and market access planning across the 7MM.Dublin, Sept. 30, 2026 (GLOBE ...

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Among patients receiving ICIs, rh-irAEs are usually moderate or severe, with more than one-third leading to ICI discontinuation.

Please provide your email address to receive an email when new articles are posted on . More than 50% of adenomas developed within 7.5 months of immune checkpoint inhibitor-mediated diarrhea and ...

Please provide your email address to receive an email when new articles are posted on . The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer ...

Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with ...